# Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

> **NCT01431456** · PHASE3 · COMPLETED · sponsor: **Martini Hospital Groningen** · enrollment: 148 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** Rivaroxaban
- **DRUG:** Nadroparin

## Key facts

- **NCT ID:** NCT01431456
- **Lead sponsor:** Martini Hospital Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2018-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431456, "Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01431456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*